92288-93-2

Usage

Uses

Used in Flavor and Fragrance Industry:
ETHYL 2,4-DIOXO-4-(2-PYRIDINYL)BUTANOATE is used as a flavor and fragrance ingredient for its distinctive fruity and aromatic scent, enhancing the sensory experience in consumer products such as perfumes, soaps, and lotions.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, ETHYL 2,4-DIOXO-4-(2-PYRIDINYL)BUTANOATE may be utilized for its potential applications, although specific uses are not detailed in the provided materials. Its low toxicity and safety profile make it a candidate for further exploration in this field.
Used in Agrochemical Industry:
ETHYL 2,4-DIOXO-4-(2-PYRIDINYL)BUTANOATE may also find applications in the agrochemical industry, potentially serving as a component in the development of products for agricultural use. The exact role it plays in this industry is not specified in the materials, but its chemical properties could be harnessed for specific purposes.

InChI:InChI=1/C11H11NO4/c1-2-16-11(15)10(14)7-9(13)8-5-3-4-6-12-8/h3-6H,2,7H2,1H3

Upstream product

• 1122-62-9 2-acetylpyridine 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 910480-79-4 1-cyclohexyl-5-pyridin-2-yl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 910480-80-7 1-cyclohexyl-5-pyridin-2-yl-1H-pyrazole-3-carbaldehyde 
• 1388021-42-8 4-(2-((4-chloro-5-(pyridin-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methylamino)pyridin-4-yl)-3-methylbenzonitrile 
• 174139-65-2 ethyl 3-(pyridin-2-yl)-1H-pyrazole-5-carboxylate 
• 893638-37-4 5-(pyridin-2-yl)-1,2-oxazole-3-carboxylic acid 

Relevant academic research and scientific papers

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat this ne

ATF6 INHIBITORS AND USES THEREOF

Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.

Discovery of phenylaminopyridine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors

We identified a novel class of aryl-substituted triazine compounds as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) during a high-throughput screening campaign that evaluated more than 200000 compounds for antihuman immunodeficiency virus (HIV) activity using a cell-based full replication assay. Herein, we disclose the optimization of the antiviral activity in a cell-based assay system leading to the discovery of compound 27, which possessed excellent potency against wild-type HIV-1 (EC50 = 0.2 nM) as well as viruses bearing Y181C and K103N resistance mutations in the reverse transcriptase gene. The X-ray crystal structure of compound 27 complexed with wild-type reverse transcriptase confirmed the mode of action of this novel class of NNRTIs. Introduction of a chloro functional group in the pyrazole moiety dramatically improved hERG and CYP inhibition profiles, yielding highly promising leads for further development.

PYRAZOLE DERIVATIVE

A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds

Benzimidazole-based allosteric inhibitors of the hepatitis C virus (HCV) NS5B polymerase were diversified to a variety of topologically related scaffolds. Replacement of the polar benzimidazole core by lipophilic indoles led to inhibitors with improved potency in the cell-based subgenomic HCV replicon system. Transposing the indole scaffold into a previously described series of benzimidazole-tryptophan amides generated the most potent inhibitors of HCV RNA replication in cell culture reported to date in this series (EC50 ～ 50 nM).

AMIDOPYRAZOLE DERIVATIVE

A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

PYRAZOLE DERIVATIVE

Not available

Acid pyrazole derivatives, preparation method therefor, use thereof as drugs, novel use therefor, and pharmaceutical compositions containing such derivatives

The subject of the invention is the products of formula (I): in which one of A and B represents a nitrogen atom and the other one of A and B represents a methine radical, such that: A represents either nitrogen substituted in particular by alkyl,